Table 1.

Main demographic, somatometric, and clinical characteristics of the study population

Whole Cohort (n = 225)<7.4 mg/L CRP and <2.4 μmol/L ADMA (n = 64)>7.4 mg/L CRP and <2.4 μmol/L ADMA (n = 47)<7.4 mg/L CRP and >2.4 μmol/L ADMA (n = 50)>7.4 mg/L CRP and >2.4 μmol/L ADMA (n = 64)P
Age (years)60 ± 1559 ± 1765 ± 1156 ± 1459 ± 150.02
Dialysis vintage (months)42 (21 to 109)27 (14 to 61)43 (25 to 77)86 (23 to 172)46 (24 to 129)<0.001
Male sex, n (%)123 (55%)34 (53%)21 (45%)24 (51%)43 (67%)0.10
Smokers, n (%)83 (37%)21 (33%)15 (32%)19 (40%)28 (44%)0.48
Diabetics, n (%)34 (15%)9 (14%)11 (23%)3 (6%)11 (17%)0.14
With CV comorbidities, n (%)113 (50%)24 (38%)31 (66%)17 (36%)40 (63%)<0.001
On anti-hypertensive treatment, n (%)82 (36%)20 (31%)12 (26%)19 (40%)30 (47%)0.09
Systolic pressure (mmHg)139 ± 25137 ± 25142 ± 30139 ± 26141 ± 210.62
Diastolic pressure (mmHg)76 ± 1377 ± 1376 ± 1375 ± 1276 ± 130.94
Cholesterol (mg/dl)208 ± 58192 ± 44217 ± 72218 ± 60209 ± 550.06
Hemoglobin (g/L)106 ± 19110 ± 19106 ± 15109 ± 19105 ± 200.32
Calcium phosphate (mmol2/L2)4.52 ± 1.124.59 ± 1.194.48 ± 1.114.41 ± 1.044.57 ± 1.140.82
Albumin (g/L)42 ± 543 ± 441 ± 442 ± 541 ± 60.14
CRP (mg/L)7.5 (3.4 to 16.4)3.4 (3.4 to 3.5)20.6 (13.7 to 30.7)3.4 (3.4 to 4.3)15.7 (11.5 to 27.7)<0.001
IL-6 (pg/ml)5.0 (2.7 to 9.2)3.3 (2.6 to 5.3)4.8 (2.9 to 10.2)4.4 (2.2 to 8.2)7.7 (4.9 to 11.8)<0.001
ADMA (μmol/L)2.52 (1.58 to 3.85)1.63 (1.06 to 1.98)1.56 (1.10 to 1.97)3.55 (2.89 to 4.69)3.99 (3.33 to 5.24)<0.001
Homocysteine (μmol/L)27.0 (19.4 to 42.7)29.3 (20.3 to 52.0)25.4 (20.0 to 38.5)26.2 (18.2 to 44.7)27.3 (19.4 to 42.7)0.41
  • The data are expressed as the means ± SD, median and interquartile range, or as the percent frequency, as appropriate. The patients were grouped according to the median values of CRP and ADMA. Comparisons among groups were made by one-way ANOVA (continuous variables) or chi-squared test (dichotomic variables) (see last column). CRP, C-reactive protein; CV, cardiovascular; ADMA, asymmetric dimethylarginine.